About

Founded

2018

Headquarters

South San Francisco, California

Industry

Biotech, Healthcare

Company Description

Neuron23™ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 leverages recent advances in human genetics, combined with their state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeutics for devastating diseases. The Company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases.

Quick Links

Website Jobs

Funding

Total Raised

$213.5 million

Valuation

Undisclosed

Significant Investors

SoftBank, Westlake Village BioPartners, Kleiner Perkins, Redmile Group, Cowen Healthcare Investments, Acorn Bioventures, HBM Partners, Perceptive Advisors, Surveyor Capital

Company Traction

As of June 2023, Neuron23 is in the pre-clinical phase for TYK2 targeting systemic inflammation and in the discovery phase for Program 3 targeting ALS.

In February 2023, Neuron23 announced the first-in-human dose in the Phase 1 clinical trial of NEU-723 to treat Parkinson’s disease.

Leadership Team

Nancy Stagliano: CEO & Chair at Neuron23. Former CEO at True North Therapeutics.

Adam Knight: Founder of Neuron23. Former EIR at Kleiner Perkins.

Steve Wood: SVP of Drug Discovery at Neuron23. Former Director of Neuroscience Research at Amgen.

Sam Jackson: Chief Medical Officer at Neuron23. Former Chief Medical Officer at Alector.

Luc Desnoyers: VP of Translational Research & Discovery at Neuron23. Former VP of Translational Sciences at CytomX Therapeutics.

Press

Neuron23 Blog (March 30, 2022): closed a $100 million Series C

Fierce Biotech (September 16, 2022): Qiagen tapped to develop companion diagnostic for Neuron23's drug for Parkinson's disease

Neuron23